Sign Up Now
Get instant access to over 1 million+ study documents
OR
Already registered? click here to login
By creating your account, you agree to our terms of service, privacy policy and student honor code.
Particularly after her PANSS test results, the client in this case has been diagnosed with schizophrenia, paranoid type, in which positive symptoms like delusions are prevalent. The purpose of this paper is to clarify three key psychopharmacological treatment decisions made on behalf of the client. Goals of all three decisions are symptom reduction and the promotion of the client's mental health and psychosocial functioning.
Decision
The decision was to give the patient Invega Sustenna (paliperidone palmitate) 234 mg intramuscular X1 followed by 156 mg intramuscular on day 4 and monthly thereafter, instead of either Zyprexa (olanzapine) or Abilify. The reasoning is based primarily on the fact that Invega Sustenna is a long-acting injectable with fewer compliance complications than orally administered drugs. Although Abilify has been available as a long-acting injectable, Invega Sustenna is recommended in this case because it presents fewer side effects than either Zyprexa or Abilify, particularly those the client has been concerned about such as weight gain (Khanna et al., 2016). Moreover, Invega Sustenna is a second-generation antipsychotic known to be "better tolerated and have fewer adverse neurological side effects" than first-generation drugs (Park, et al., 2013, p. 651).
The client returned to the clinic for follow-up four weeks after the initial injection...
The PANSS was re-administered and the client's score decreased by 25%, revealing improvement. The client reports no troublesome side effects from the medication, although she complains of immediate pain at the injection site that lasts for several hours as well as some weight gain. However, neither of these are serious complications. The husband has agreed to take the client for further injections. It is believed that the switch from orally administered antipsychotics will be beneficial for this client, and it is strongly recommended that the client stay with Invega Sustenna given the promising initial results of the PANSS test.
Decision 2
Because the client expressed concern over not being able to sit or walk comfortably after the injection, it was recommended that the administering nurse inject at the deltoid site instead. As pain at the injection site is a concern due to the need to maintain patient compliance with the medication schedule, switching the site should not be a problem.
This decision worked well, as the client directly told the nurses that the pain was much less problematic at the arm site. However, the client has gained more weight -- up again from the first injection to now a total of 4.5 pounds over two months. The client claims that "her husband might not like it," referring to the weight gain, but…
References
Amiaz, R., Rubenstein, K., Czerniak, E. et al. (2016). A Diet and Fitness Program Similarly Affects Weight Reduction in Schizophrenia Patients Treated with Typical or Atypical Medications. Pharmacopsychiatry 49(3): 112-116.
Bak, M., et al. (2014). Almost All Antipsychotics Result in Weight Gain: A Meta-Analysis. PLoS ONE 9(4): e94112. doi:10.1371/journal.pone.0094112
Khanna, et al. (2016). Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2014, Issue 1. Art. No.: CD006569. DOI: 10.1002/14651858.CD006569.pub5.
Park, E.J. et al. (2013). Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia. Archives of Pharmacal Research 36(6): 651-659.
Potkin, S.G. et al. (2016). Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate. International Journal of Neuropsychopharmacology. DOI: http://dx.doi.org/10.1093/ijnp/pyw093
Schizophrenia When people think of what it means to 'go crazy,' quite often the common image that comes to mind is that of someone with schizophrenia. Schizophrenia is a serious mental health disorder that can be physically, socially, and personally destabilizing. "Schizophrenia affects men and women equally. It occurs at similar rates in all ethnic groups around the world. Symptoms such as hallucinations and delusions usually start between ages 16 and
Antipsychotic Medication and the Physical Health Problems of the Patient With Mental Illness More and more attention is now being given to the mental disorders especially in U.S. And due to this increase in attention an increase has also been noticed in the treatment of these mental health issues (Zuvekas, 2005). About 30% of the total U.S. population that is between the ages of 18-52 is being affected by mental health
There is usually a gap of one or two years between the appearance of vague symptoms and the patient's visit to a psychiatric clinic. Neurological examination may reveal a link between schizophrenia and Wilson's disease and Huntington's disease before treatment starts. The disorder has also been associated with left and mixed handedness, some physical abnormalities and mild neurological signs (Frankenburg). Mental status examination often reveals odd and poorly understood behaviors,
Psychopharmacological Approaches to Treat PsychopathologyNameProgram/Degree NameCourseInstructorDatePsychopharmacological Approaches to Treat PsychopathologySchizophrenia and its spectrum disorders are disruptive disorders that significantly impact the normal processes of the brain (Chien & Yip, 2013). These disruptive disorders are linked to significant abnormalities because they interfere with the ability to think. Patients may struggle to function normally when the symptoms of these disruptive disorders are not controlled or managed. However, proper diagnosis and treatment of
By educating patients on early warning signs of hepatotoxicity, this rare but potentially fatal consequence could be detected early to allow appropriate intervention." (Wright and Vandenberg, 2007) it is extremely critical to understand the nature of psychiatric nursing in today's clinical environment. IV. ROLE of NURSE PRACTITIONER in TRANSITION Specifically stated in the work of Kathryn R. Puskar entitled; "The Nurse Practitioner Role in Psychiatric Nursing" published in the Online Journal
Therapeutic communities are important and valuable tools, but certainly not for all patients. Often, the community is made up of a certain ward or unit of the hospital, rather than the entire facility. Clearly, some patients, such as those suffering from serious debilitating diseases such as dementia or severe schizophrenia might not be physically or mentally able to exist in such a facility. However, for others, who have specific issues